Organon stops work on drug once viewed as ‘game-chang­ing’; Next­Point culls an as­set

Plus, news about Ar­riVent Bio­Phar­ma, Ever­est Med­i­cines, Ri­bo­cure, Par­a­digm Bio­phar­ma­ceu­ti­cals, Ver­ri­ca and Torii:

Organon dis­con­tin­ues ex­per­i­men­tal ther­a­py for en­dometrio­sis-re­lat­ed pain: The Mer­ck spin­out said the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER